Bacoside A

Bacoside A at a Glance

“Bacoside A” is the name given to the principal nootropic marker of Bacopa monnieri (brahmi, water hyssop) — the compound to which standardized Bacopa extracts are titrated and around which the herb’s memory research is built. The single most important thing to understand about it is that it is not one molecule. Bacoside A is a standardized mixture of dammarane-type triterpenoid saponins — chiefly bacoside A3, bacopaside II, a jujubogenin isomer of bacopasaponin C (bacopaside X), and bacopasaponin C — jujubogenin and pseudojujubogenin glycosides that co-elute and were historically reported together ^{1Reference 1Deepak M et al. · 2005Quantitative determination of the major saponin mixture bacoside A in Bacopa monnieri by HPLCView study →}.

That framing matters for how the evidence reads. Because the standardized extracts used in Bacopa’s human trials (CDRI 08 / KeenMind and BacoMind) are titrated to a fixed bacoside content, “bacoside A” is the closest thing this batch of saponins has to direct clinical evidence — controlled trials, a systematic review and a meta-analysis in human memory and cognition ^{7,8,9Reference 7Benson S et al. · 2014RCTAn acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and moodView study →Reference 8Pase MP et al. · 2012Systematic reviewThe cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trialsView study →Reference 9Kongkeaw C et al. · 2014Meta-analysisMeta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extractView study →}. The honest caveat is that those trials give a standardized whole-herb extract, not purified bacoside A, and component-specific molecular data belong to the individual saponins (bacopaside I, bacopaside II) rather than to the mixture as a whole.

The mechanistic story is cholinergic, antioxidant and anti-inflammatory action in the brain, with additional effects on cerebral blood flow and neurotransmitter systems. Tolerability in trials is good; the main real-world issue is gastrointestinal upset.

What “Bacoside A” Actually Is

The label is a historical artefact of chromatography. When Bacopa’s saponins were first fractionated, several co-eluted under one peak called “bacoside A”; modern HPLC resolved that peak into four major saponins. Deepak and colleagues quantified them across Indian Bacopa samples ^{1Reference 1Deepak M et al. · 2005Quantitative determination of the major saponin mixture bacoside A in Bacopa monnieri by HPLCView study →}:

Component saponin	Class	Reported content (% dry herb)
Bacoside A3	Jujubogenin glycoside	0.14–0.85%
Bacopaside II	Pseudojujubogenin glycoside	0.12–0.69%
Jujubogenin isomer of bacopasaponin C (bacopaside X)	Jujubogenin glycoside	0.05–0.72%
Bacopasaponin C	Jujubogenin glycoside	0.05–0.44%

Two consequences follow. First, “standardized to X% bacosides” is a mixture spec, not a single-compound assay, and the ratio of the four shifts with genotype, region and processing ^{1Reference 1Deepak M et al. · 2005Quantitative determination of the major saponin mixture bacoside A in Bacopa monnieri by HPLCView study →}. Second, when a study reports an effect of “bacoside A,” it is reporting the effect of that whole saponin bundle — the individual contributions of bacoside A3 versus bacopaside II are rarely separated. Where a mechanism has been pinned to one saponin, it is attributed to that molecule and cross-links its page.

What It's Used For

Unusually for a plant saponin, bacoside A anchors a body of human evidence — because the standardized Bacopa extracts trialled in cognition and mood are defined by their bacoside content ^{7,8,9Reference 7Benson S et al. · 2014RCTAn acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and moodView study →Reference 8Pase MP et al. · 2012Systematic reviewThe cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trialsView study →Reference 9Kongkeaw C et al. · 2014Meta-analysisMeta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extractView study →}. The load-bearing caveat is the inverse of most compound pages: here the human data are strong but are the extract, while the isolated-saponin mechanism work is preclinical.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Memory scores higher than a typical saponin because the extract has controlled human trials, but the score is for the standardized extract, not purified bacoside A.

01Memory & LearningPromising62%Multiple human RCTs + systematic review + meta-analysis of standardized extract ^{2,3,4,5,8,9Reference 2Stough C et al. · 2001Clinical trialThe chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjectsView study →Reference 3Roodenrys S et al. · 2002Chronic effects of Brahmi (Bacopa monnieri) on human memoryView study →Reference 4Calabrese C et al. · 2008RCTEffects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trialView study →Reference 5Morgan A · 2010RCTDoes Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trialView study →Reference 8Pase MP et al. · 2012Systematic reviewThe cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trialsView study →Reference 9Kongkeaw C et al. · 2014Meta-analysisMeta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extractView study →}

02Attention & Cognitive ProcessingPromising52%Human RCTs on processing speed / working memory; acute crossover ^{6,7,9Reference 6Peth-Nui T et al. · 2012Effects of 12-week Bacopa monnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteersView study →Reference 7Benson S et al. · 2014RCTAn acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and moodView study →Reference 9Kongkeaw C et al. · 2014Meta-analysisMeta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extractView study →}

03AnxietyShaky40%Human extract RCT (secondary outcome) + rodent anxiolytic isolate/extract work ^{4,10Reference 4Calabrese C et al. · 2008RCTEffects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trialView study →Reference 10Bhattacharya SK · 1998Anxiolytic activity of a standardized extract of Bacopa monniera: an experimental studyView study →}

04Neuroprotection & AntioxidantShaky38%Rodent antioxidant + anti-amyloid + AD-model studies ^{13,14,15,16,17Reference 13Nemetchek MD et al. · 2017The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brainView study →Reference 14Bhattacharya SK et al. · 2000AnimalAntioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampusView study →Reference 15Dhanasekaran M et al. · 2007Neuroprotective mechanisms of ayurvedic antidementia botanical Bacopa monnieraView study →Reference 16Holcomb LA et al. · 2006AnimalBacopa monniera extract reduces amyloid levels in PSAPP miceView study →Reference 17Uabundit N et al. · 2010Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer’s disease modelView study →}

05AntidepressantShaky30%Rodent extract/saponin models; human depression outcome secondary/null ^{4,11,12Reference 4Calabrese C et al. · 2008RCTEffects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trialView study →Reference 11Sairam K et al. · 2002AnimalAntidepressant activity of standardized extract of Bacopa monniera in experimental models of depression in ratsView study →Reference 12Zhou Y et al. · 2007AnimalTriterpene saponins from Bacopa monnieri and their antidepressant effects in two mice modelsView study →}

06Anti-inflammatory (CNS)Shaky30%In-vitro microglial cytokine suppression by the plant/bacosides ^{13Reference 13Nemetchek MD et al. · 2017The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brainView study →}

Mechanisms

Pharmacokinetics

Bacoside A carries the generic saponin PK liability: large, highly glycosylated triterpene molecules with poor passive membrane permeability, extensive gastric and gut-microbial hydrolysis, and low oral bioavailability — the aglycones (jujubogenin, pseudojujubogenin) are the likely absorbed species after deglycosylation. This is exactly why bacoside gains are slow and require weeks of dosing rather than acting acutely, and why formulation research targets the bioavailability barrier — e.g. a thermosensitive intranasal gel was developed specifically to bypass poor oral/blood-brain delivery of bacoside A ^{21Reference 21Mankar SD et al. · 2024Formulation, optimization and in-vivo characterization of thermosensitive in-situ nasal gel loaded with bacoside AView study →}. A defined human ADME profile for bacoside A — oral bioavailability figure, Cmax, half-life, CNS penetration — is not established; PK data are fragmentary and largely preclinical. The clinical effect is therefore read from the extract’s behavioural results, not from a known plasma/brain concentration of the saponin.

Clinical Trials

Human trials use standardized Bacopa extract (CDRI 08 / KeenMind, BacoMind), defined by bacoside content — not purified bacoside A. The evidence base is one of the more substantial in botanical nootropics.

Last checked: July 2026.

How Bacoside A Works

No single receptor explains bacoside A; its cognitive effect is best read as several converging brain-protective actions in the memory-relevant regions.

Cholinergic Modulation

The cholinergic system governs memory, and bacosides act on it. A 12-week human trial linked cognitive improvement to a change in plasma acetylcholinesterase activity ^{6Reference 6Peth-Nui T et al. · 2012Effects of 12-week Bacopa monnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteersView study →}, and in an Alzheimer’s lesion model Bacopa’s benefit was partly mediated by suppressed acetylcholinesterase ^{17Reference 17Uabundit N et al. · 2010Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer’s disease modelView study →}, raising synaptic acetylcholine availability.

Antioxidant Defence

Bacopa raises endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase) in the frontal cortex, striatum and hippocampus ^{14Reference 14Bhattacharya SK et al. · 2000AnimalAntioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampusView study →}, reducing the oxidative burden implicated in cognitive aging — the core of the “antioxidant therapy for the aging brain” framing ^{13Reference 13Nemetchek MD et al. · 2017The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brainView study →}.

Anti-Neuroinflammation

Bacopa suppresses microglial pro-inflammatory signalling — lowering TNF-α, IL-6, caspase-1/3 and MMP-3 ^{13Reference 13Nemetchek MD et al. · 2017The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brainView study →} — restraining the neuroinflammatory component of age- and injury-related cognitive decline.

Cerebral Blood Flow

Bacopa increases cerebral blood flow independent of blood pressure in rats ^{19Reference 19Kamkaew N et al. · 2013AnimalBacopa monnieri increases cerebral blood flow in rat independent of blood pressureView study →}, a haemodynamic route to improved cognitive substrate that complements the cellular mechanisms.

Neurotransmitter & GABAergic Effects

In epileptic rat hippocampus, bacoside A reversed the down-regulation of GABAA-receptor functional regulation ^{18Reference 18Mathew J et al. · 2011AnimalBehavioral deficit and decreased GABA receptor functional regulation in the hippocampus of epileptic rats: effect of Bacopa monnieri and bacoside-AView study →}, consistent with the herb’s anticonvulsant and anxiolytic signals ^{10Reference 10Bhattacharya SK · 1998Anxiolytic activity of a standardized extract of Bacopa monniera: an experimental studyView study →}.

Synaptic & Dendritic Support

Preclinical work attributes part of the memory effect to enhanced dendritic arborization and synaptic plasticity in the hippocampus, a structural correlate of improved learning.

A Unifying Interpretation

Bacoside A’s disparate findings collapse into one economical read: it is a brain-protective saponin complex whose behavioural benefit — better delayed recall, calmer mood — is the downstream sum of raised antioxidant defence, restrained neuroinflammation, supported cholinergic transmission and improved cerebral perfusion, playing out over weeks in the hippocampus and cortex. This is why the human effect is slow and modest rather than acute and dramatic: it is a maintenance/protection mechanism, not a stimulant hit. The caveat threads through the whole picture — nearly all of it is the standardized extract, and the individual weight of each component saponin (bacoside A3 vs. bacopaside II) inside “bacoside A” is not resolved.

Bacoside A vs. Its Component Saponins

Because bacoside A is a mixture, molecular claims should be attributed with care:

• Bacoside A3 — the jujubogenin glycoside present at the highest concentration in most samples ^{1Reference 1Deepak M et al. · 2005Quantitative determination of the major saponin mixture bacoside A in Bacopa monnieri by HPLCView study →}; treated as a principal marker but rarely tested in isolation.
• Bacopaside II — a pseudojujubogenin glycoside and a defined member of the bacoside A peak ^{1Reference 1Deepak M et al. · 2005Quantitative determination of the major saponin mixture bacoside A in Bacopa monnieri by HPLCView study →}; carries its own isolated antidepressant and mechanistic data ^{12Reference 12Zhou Y et al. · 2007AnimalTriterpene saponins from Bacopa monnieri and their antidepressant effects in two mice modelsView study →}.
• Bacopaside I — a closely related pseudojujubogenin saponin (a Bacopa marker often quantified alongside bacoside A); antidepressant-active in mice ^{12Reference 12Zhou Y et al. · 2007AnimalTriterpene saponins from Bacopa monnieri and their antidepressant effects in two mice modelsView study →}. Note some assays report “bacoside A + bacopaside I” together as the standardizing figure.
• Bacopasaponin C (and its jujubogenin isomer, bacopaside X) — the remaining two major components of the peak ^{1Reference 1Deepak M et al. · 2005Quantitative determination of the major saponin mixture bacoside A in Bacopa monnieri by HPLCView study →}; bacopasaponin C is antidepressant-active in the same mouse screen ^{12Reference 12Zhou Y et al. · 2007AnimalTriterpene saponins from Bacopa monnieri and their antidepressant effects in two mice modelsView study →}.

When a paper says “bacoside A,” read it as this bundle; when it names a single saponin, the finding belongs to that molecule’s page.

Isolate vs. Plant Studies

The evidence split here is the near-mirror of most compound pages. The human clinical evidence is a plant extract — every memory/cognition RCT, the systematic review and the meta-analysis give a standardized Bacopa extract (CDRI 08, BacoMind) defined by bacoside content, never purified bacoside A ^{7,8,9Reference 7Benson S et al. · 2014RCTAn acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and moodView study →Reference 8Pase MP et al. · 2012Systematic reviewThe cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trialsView study →Reference 9Kongkeaw C et al. · 2014Meta-analysisMeta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extractView study →}. The isolated-saponin evidence is preclinical — the antidepressant screen of individual bacopasides/bacopasaponin C in mice ^{12Reference 12Zhou Y et al. · 2007AnimalTriterpene saponins from Bacopa monnieri and their antidepressant effects in two mice modelsView study →}, and mechanistic antioxidant/anti-inflammatory/GABA work at the extract or fraction level ^{13,14,18Reference 13Nemetchek MD et al. · 2017The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brainView study →Reference 14Bhattacharya SK et al. · 2000AnimalAntioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampusView study →Reference 18Mathew J et al. · 2011AnimalBehavioral deficit and decreased GABA receptor functional regulation in the hippocampus of epileptic rats: effect of Bacopa monnieri and bacoside-AView study →}. This is actually a favourable posture: the marker used to standardize the herb is the same fraction the human trials are titrated to, so the isolate and the clinical vehicle are unusually well aligned — but the purified mixture given alone has not been tested in people, and no single component has a human efficacy trial.

Prevalence in Nature

Bacoside A is effectively unique to Bacopa monnieri (brahmi / water hyssop, family Plantaginaceae) — a creeping wetland herb of India, Southeast Asia and other tropical regions. Its four component saponins together total roughly 0.4–2.7% of the dry herb, but the content is highly variable: Deepak’s survey of Indian samples found several-fold ranges for each component across collection regions, and genotype, season, plant part and extraction method all shift the total and the ratio ^{1Reference 1Deepak M et al. · 2005Quantitative determination of the major saponin mixture bacoside A in Bacopa monnieri by HPLCView study →}. Commercial standardized extracts are titrated to a fixed percentage of total bacosides precisely to control for this variability — the raw herb, tea or unstandardized powder does not carry a reliable bacoside dose ^{20Reference 20Simpson T et al. · 2015Bacopa monnieri as an antioxidant therapy to reduce oxidative stress in the aging brainView study →}. Trace jujubogenin/pseudojujubogenin saponins occur elsewhere in the plant kingdom (e.g. in Ziziphus, the source of jujubogenin), but the specific bacoside A complex is a Bacopa signature.

Discovery & Synthesis

“Bacoside A” entered the literature as the saponin-fraction name for the active principle of Bacopa monnieri in mid-20th-century Indian phytochemistry, when the herb (Sanskrit brahmi, a classical Ayurvedic medhya rasayana / cognitive tonic) was first chemically investigated. For decades it was treated as a compound; the modern understanding — that it is a co-eluting mixture of four dammarane saponins — was established when Deepak and colleagues resolved and quantified bacoside A3, bacopaside II, the jujubogenin isomer of bacopasaponin C, and bacopasaponin C by HPLC and proposed using the defined mixture as a reference standard ^{1Reference 1Deepak M et al. · 2005Quantitative determination of the major saponin mixture bacoside A in Bacopa monnieri by HPLCView study →}. There is no total synthesis of “bacoside A” — as a mixture, the concept does not admit one; the individual saponins are complex glycosides obtained by extraction and chromatographic isolation from the herb, and manufacture today is entirely botanical (standardized-extract production titrated to bacoside content).

Patents: not yet researched.

Toxicity & Safety

Bacoside A earns a low flag on the strength of its clinical record: standardized Bacopa extracts have been given to healthy adults, older people and (in other work) children across multi-week randomized trials with good tolerability and no serious adverse events ^{2,4,8Reference 2Stough C et al. · 2001Clinical trialThe chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjectsView study →Reference 4Calabrese C et al. · 2008RCTEffects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trialView study →Reference 8Pase MP et al. · 2012Systematic reviewThe cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trialsView study →}. The consistent, dose-related complaint is gastrointestinal — nausea, cramping, increased stool frequency and dry mouth — attributed in part to the cholinergic action and the saponins’ gut irritancy, and usually mild ^{8Reference 8Pase MP et al. · 2012Systematic reviewThe cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trialsView study →}. This is a mixture/extract-level safety read; a dedicated toxicology of purified bacoside A is thin, and the usual saponin caveat (hemolytic at high concentration in vitro) applies to the isolated compound rather than to oral herb intake.

Safety at a Glance

✅ Low / no toxicity

• Good clinical tolerability. Standardized Bacopa extract has been dosed for weeks in multiple RCTs without serious adverse events ^{2,4,8Reference 2Stough C et al. · 2001Clinical trialThe chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjectsView study →Reference 4Calabrese C et al. · 2008RCTEffects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trialView study →Reference 8Pase MP et al. · 2012Systematic reviewThe cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trialsView study →}.
• GI upset is the common complaint. Nausea, cramping, loose stools and dry mouth — dose-related and cholinergic, usually mild ^{8Reference 8Pase MP et al. · 2012Systematic reviewThe cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trialsView study →}.
• Cholinergic additivity, in principle. As a cholinergic-active fraction it could in theory interact with cholinergic or anticholinergic drugs; not well quantified in humans ^{6,17Reference 6Peth-Nui T et al. · 2012Effects of 12-week Bacopa monnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteersView study →Reference 17Uabundit N et al. · 2010Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer’s disease modelView study →}.
• Standardization matters. Safety and effect data are for standardized extracts (CDRI 08 / BacoMind); raw herb, tea and unstandardized powder carry an unreliable bacoside dose ^{20Reference 20Simpson T et al. · 2015Bacopa monnieri as an antioxidant therapy to reduce oxidative stress in the aging brainView study →}.
• Pregnancy/lactation not established. No reproductive-safety data for the isolate; the intake decision belongs on the Bacopa herb page.

Dosage

There is no established dose of isolated bacoside A. The human evidence uses standardized Bacopa monnieri extract (CDRI 08 / KeenMind, BacoMind) at roughly 300–450 mg/day, standardized to a fixed bacoside content, taken for 8–12 weeks before the cognitive effect emerges ^{2,4,7Reference 2Stough C et al. · 2001Clinical trialThe chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjectsView study →Reference 4Calabrese C et al. · 2008RCTEffects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trialView study →Reference 7Benson S et al. · 2014RCTAn acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and moodView study →}.

The effect is slow and cumulative, not acute — a several-week course, not a single dose. These are doses of standardized extract studied in research, not purified bacoside A, and are not a personal recommendation.

References

1. Deepak M, Sangli GK, Arun PC, Amit A. (2005). Quantitative determination of the major saponin mixture bacoside A in Bacopa monnieri by HPLC. Phytochemical Analysis. https://pubmed.ncbi.nlm.nih.gov/15688952/
2. Stough C, et al. (2001). The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl). https://pubmed.ncbi.nlm.nih.gov/11498727/
3. Roodenrys S, et al. (2002). Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. https://pubmed.ncbi.nlm.nih.gov/12093601/
4. Calabrese C, et al. (2008). Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. Journal of Alternative and Complementary Medicine. https://pubmed.ncbi.nlm.nih.gov/18611150/
5. Morgan A, Stevens J. (2010). Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. Journal of Alternative and Complementary Medicine. https://pubmed.ncbi.nlm.nih.gov/20590480/
6. Peth-Nui T, et al. (2012). Effects of 12-week Bacopa monnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteers. Evidence-Based Complementary and Alternative Medicine. https://pubmed.ncbi.nlm.nih.gov/23320031/
7. Benson S, et al. (2014). An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/23788517/
8. Pase MP, et al. (2012). The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. Journal of Alternative and Complementary Medicine. https://pubmed.ncbi.nlm.nih.gov/22747190/
9. Kongkeaw C, et al. (2014). Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/24252493/
10. Bhattacharya SK, Ghosal S. (1998). Anxiolytic activity of a standardized extract of Bacopa monniera: an experimental study. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/23195757/
11. Sairam K, et al. (2002). Antidepressant activity of standardized extract of Bacopa monniera in experimental models of depression in rats. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/12046860/
12. Zhou Y, et al. (2007). Triterpene saponins from Bacopa monnieri and their antidepressant effects in two mice models. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/17343408/
13. Nemetchek MD, et al. (2017). The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/27473605/
14. Bhattacharya SK, et al. (2000). Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/10815010/
15. Dhanasekaran M, et al. (2007). Neuroprotective mechanisms of ayurvedic antidementia botanical Bacopa monniera. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/17604373/
16. Holcomb LA, et al. (2006). Bacopa monniera extract reduces amyloid levels in PSAPP mice. Journal of Alzheimer’s Disease. https://pubmed.ncbi.nlm.nih.gov/16914834/
17. Uabundit N, et al. (2010). Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer’s disease model. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/19808086/
18. Mathew J, et al. (2011). Behavioral deficit and decreased GABA receptor functional regulation in the hippocampus of epileptic rats: effect of Bacopa monnieri and bacoside-A. Neurochemical Research. https://pubmed.ncbi.nlm.nih.gov/20821261/
19. Kamkaew N, et al. (2013). Bacopa monnieri increases cerebral blood flow in rat independent of blood pressure. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/22447676/
20. Simpson T, et al. (2015). Bacopa monnieri as an antioxidant therapy to reduce oxidative stress in the aging brain. Evidence-Based Complementary and Alternative Medicine. https://pubmed.ncbi.nlm.nih.gov/26413126/
21. Mankar SD, et al. (2024). Formulation, optimization and in-vivo characterization of thermosensitive in-situ nasal gel loaded with bacoside A. AAPS PharmSciTech. https://pubmed.ncbi.nlm.nih.gov/38954171/

View all 21 references▾